Drug Profile

Atuliflapon - AstraZeneca

Alternative Names: AZD-5718

Latest Information Update: 11 May 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator AstraZeneca
Class Amides; Antiasthmatics; Cardiovascular therapies; Pyrans; Pyrazines; Pyrazoles; Small molecules; Urologics; Vascular disorder therapies
Mechanism of Action 5-lipoxygenase-activating protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Phase II Acute coronary syndromes
Discontinued Asthma; Cardiovascular disorders; Coronary artery disease; Renal failure

31 Mar 2026 Discontinued - Phase-II for Asthma (Treatment-experienced, In adults, In the elderly) in USA, Poland, Netherlands, Japan, Hungary, United Kingdom, Ukraine, Turkey, Spain, South Korea, South Africa, Slovakia, Serbia, Romania, Germany, Chile, Argentina, Croatia (PO), due to lack of efficacy (NCT05251259) (EudraCT2021-003338-35) (AstraZeneca pipeline, May 2026)
31 Mar 2026 AstraZeneca terminates the phase-II FLASH trial in Asthma (Treatment-experienced, In adults, In the elderly) in USA, Poland, Netherlands, Japan, Hungary, United Kingdom, Ukraine, Turkey, Spain, South Korea, South Africa, Slovakia, Serbia, Romania, Germany, Chile, Argentina, Croatia (PO), due to lack of efficacy (NCT05251259) (EudraCT2021-003338-35) (AstraZeneca pipeline, May 2026)
27 Jan 2026 AstraZeneca completes a phase-II clinical trials in Asthma (Treatment-experienced, In adults, In the elderly) in USA, Poland, Netherlands, Japan, Hungary, United Kingdom, Ukraine, Turkey, Spain, South Korea, South Africa, Slovakia, Serbia, Romania, Germany, Chile, Argentina, Croatia (PO) (NCT05251259) (EudraCT2021-003338-35)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com